Advertisement

Dynamic 18F-Fluoride Imaging

  • Homer A. Macapinlac
  • Kalevi Kairemo
Chapter
Part of the Clinicians’ Guides to Radionuclide Hybrid Imaging book series (CGRHI)

Abstract

Diseases affecting bone metabolism involve a wide range of skeletal and soft tissue disorders. They may be grouped as osteoporosis, osteomalacia, hyperparathyroidism, Paget’s disease of bone, and developmental disorders of bone. Age-related osteoporosis alone affects about 28 million Americans, and the cost of caring for osteoporosis-related fractures has recently been estimated to be about $14.8 billion each year.

References

  1. 1.
    Blake GM, Puri T, Siddique M, Frost ML, Moore AEB, Fogelman I. Site specific measurements of bone formation using [18F] sodium fluoride PET/CT. Quant Imaging Med Surg. 2018;8(1):47–59.  https://doi.org/10.21037/qims.2018.01.02.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hawkins RA, Choi Y, Huang SC, Hoh CK, Dahlbom M, Schiepers C, Satyamurthy N, Barrio JR, Phelps ME. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33:633–42.PubMedGoogle Scholar
  3. 3.
    Blake GM, Siddique M, Puri T, Frost ML, Moore AE, Cook GJ, Fogelman I. A semipopulation input function for quantifying static and dynamic 18F-fluoride PET scans. Nucl Med Commun. 2012;33:881–8.CrossRefGoogle Scholar
  4. 4.
    Siddique M, Frost ML, Moore AE, Fogelman I, Blake GM. Correcting 18F-fluoride PET static scan measurements of skeletal plasma clearance for tracer efflux from bone. Nucl Med Commun. 2014;35:303–10.CrossRefGoogle Scholar
  5. 5.
    Sachpekidis C, Hillengass J, Goldschmidt H, Anwar H, Haberkorn U, Dimitrakopoulou-Strauss A. Quantitative analysis of 18F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. Am J Nucl Med Mol Imaging. 2017;7(4):148–56.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Sachpekidis C, Hillengass J, Goldschmidt H3, Wagner B, Haberkorn U, Kopka K, Dimitrakopoulou-Strauss A. Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. Eur J Nucl Med Mol Imaging. 2017;44(1):50–62.CrossRefGoogle Scholar
  7. 7.
    Simoncic U, Perlman S, Liu G, Staab MJ, Straus JE, Jeraj R. Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer. 2015;13(1):e7–e17.  https://doi.org/10.1016/j.clgc.2014.07.001.CrossRefPubMedGoogle Scholar
  8. 8.
    Jenkins NW, Talbott JF, Shah V, Pandit P, Seo Y, Dillon WP, Majumdar S. [18F]-sodium fluoride PET MR-based localization and quantification of bone turnover as a biomarker for facet joint-induced disability. AJNR Am J Neuroradiol. 2017;38(10):2028–31.  https://doi.org/10.3174/ajnr.A5348.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Adesanya O, Sprowson A, Masters J, Hutchinson C. Review of the role of dynamic 18F-NaF PET in diagnosing and distinguishing between septic and aseptic loosening in hip prosthesis. J Orthop Surg Res. 2015;10:5.  https://doi.org/10.1186/s13018-014-0147-7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Freesmeyer M, Stecker FF, Schierz JH, Hofmann GO, Winkens T. First experience with early dynamic (18)F-NaF-PET/CT in patients with chronic osteomyelitis. Ann Nucl Med. 2014;28(4):314–21.  https://doi.org/10.1007/s12149-014-0810-4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Homer A. Macapinlac
    • 1
  • Kalevi Kairemo
    • 2
  1. 1.Department of Nuclear MedicineUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of Nuclear Medicine and Molecular RadiotherapyDocrates Cancer CenterHelsinkiFinland

Personalised recommendations